Concord Biotech Limited

CONCORDBIO

INE338H01029

Pharmaceuticals

Delayed NSE India S.E. Other stock markets 06:29:59 2024-06-03 am EDT			5-day change	1st Jan Change
1,447 ^INR	-1.13%		+0.43%	-1.69%

May. 23	Concord Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
May. 23	Concord Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Concord Biotech Limited Announces Resignation of Utpal Hemendra Sheth as Independent Director

September 30, 2023 at 05:26 am EDT

Concord Biotech Limited announced that Mr. Utpal Hemendra Sheth (DIN: 00081012), Independent Director of the Company has tendered his resignation as the Independent Director of the Company, with effect from 30th September, 2023.

Latest news about Concord Biotech Limited

Concord Biotech Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 23	CI
Concord Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	May. 23	CI
Concord Biotech Limited Recommends Dividend for the Financial Year 2023-24	May. 23	CI
Concord Biotech Limited(BSE:543960) added to S&P Global BMI Index	Mar. 17	CI
Concord Biotech's API Plant Gets GMP Certificate from Brazilian Health Regulator	Mar. 06	MT
Concord Biotech Limited Receives Certificate from Brazilian Health Regulatory Agency	Mar. 06	CI
India's Nifty 50 set to hit record high at open, surfing global rally	Feb. 22	RE
Jefferies Adjusts Concord Biotech’s Price Target to INR1,410 From INR1,440, Keeps at Hold	Feb. 12	MT
Certain Equity Shares of Concord Biotech Limited are subject to a Lock-Up Agreement Ending on 11-FEB-2024.	Feb. 10	CI
Concord Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
Jefferies Downgrades Concord Biotech to Hold From Buy, Adjusts Price Target to INR1,300 From INR1,260	Nov. 10	MT
India's Cello World surges 29% on listing at $2.1 bln valuation	Nov. 06	RE
Indian cookware maker Cello World's IPO garners strong response	Nov. 01	RE
India's IRM Energy slides 11% in debut trade at over $200 million valuation	23-10-26	RE
India's JSW Infrastructure jump 20% in pre-open trading debut	23-10-03	RE
Concord Biotech Limited Announces Resignation of Utpal Hemendra Sheth as Independent Director	23-09-30	CI
India's JSW Infrastructure receives bids worth $7.3 billion in IPO	23-09-27	RE
Quadria Capital aims to raise up to $1 billion for new Asia healthcare fund	23-09-22	RE
Concord Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-09-06	CI
India's Aeroflex Industries soars over 81% in debut trade	23-08-31	RE
Concord Biotech Limited Announces Resignation of Anil Katyal as Independent Director	23-08-25	CI
US FDA Clears Concord Biotech's Manufacturing Plant in Gujarat, India	23-08-22	MT
Concord Biotech Limited Announces Cessation of Amit Varma as Non-Executive Non-Independent Director	23-08-19	CI
Concord Biotech Limited has completed an IPO in the amount of INR 15.505208 billion.	23-08-09	CI

Chart Concord Biotech Limited

Duration

Period

More charts

Company Profile

Concord Biotech Limited is an India-based research and development driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The Company manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic processes and finished formulations. It manufactures fermentation and semi-synthetic based products in the therapeutic segments, such as immunosuppressants, anti-bacterial, oncology, anti-fungal and others. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Vancomycin Hydrochloride, Micafungin Sodium, Mupirocin, Romidepsin, Dactinomycin, and Pravastatin Sodium, among others. It also has a pipeline of API products under development. Its API products under development include Polymyxin B, Fidaxomicin, Doxorubicin, and others. The Company provides products in the critical care, immunology, nephrology, and transplant medicine segments.

Sector

Pharmaceuticals

Calendar

2024-06-29 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1,464 INR

Average target price

1,592 INR

Spread / Average Target

+8.78%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
CONCORD BIOTECH LIMITED	-1.69%	1.83B
CSL LIMITED	-1.85%	89.87B
SAMSUNG BIOLOGICS CO.,LTD.	-3.95%	37.57B
UCB	+62.04%	26.47B
BIOMARIN PHARMACEUTICAL INC.	-22.14%	14.25B
INCYTE CORPORATION	-7.96%	12.99B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.33%	11.93B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-46.33%	10.84B
SWEDISH ORPHAN BIOVITRUM AB	+4.42%	9.11B
INNOVENT BIOLOGICS, INC.	-19.53%	7.32B

Biopharmaceuticals